Ho YS, Adroub SA, Aleisa F, Mahmood H, Othoum G, Rashid F, et al. Complete Genome Sequence of Mycobacterium fortuitum subsp. fortuitum Type Strain DSM46621. J Bacteriol. 2012 Nov. 194(22):6337-8. [QxMD MEDLINE Link]. [Full Text].
Velayati AA, Farnia P, Mozafari M, Malekshahian D, Seif S, Rahideh S, et al. Molecular epidemiology of nontuberculous mycobacteria isolates from clinical and environmental sources of a metropolitan city. PLoS One. 2014. 9 (12):e114428. [QxMD MEDLINE Link].
Xess AB, Bala K, Panigrahy A, Singh U. Mycobacterium fortuitum as a cause of acute CNS infection in an immune-competent girl undergoing repeated VP shunt surgeries. BMJ Case Rep. 2019 Apr 15. 12 (4):[QxMD MEDLINE Link].
Winthrop KL, Abrams M, Yakrus M, Schwartz I, Ely J, Gillies D, et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med. 2002 May 2. 346(18):1366-71. [QxMD MEDLINE Link].
Griffin I, Schmitz A, Oliver C, et al. Outbreak of Tattoo-Associated Nontuberculous Mycobacterial Skin Infections. Clin Infect Dis. 2018 Nov 17. [QxMD MEDLINE Link].
Okamori S, Asakura T, Nishimura T, Tamizu E, Ishii M, Yoshida M, et al. Natural history of Mycobacterium fortuitum pulmonary infection presenting with migratory infiltrates: a case report with microbiological analysis. BMC Infect Dis. 2018 Jan 2. 18 (1):1. [QxMD MEDLINE Link].
Franco-Paredes C, Marcos LA, Henao-Martínez AF, Rodríguez-Morales AJ, Villamil-Gómez WE, Gotuzzo E, et al. Cutaneous Mycobacterial Infections. Clin Microbiol Rev. 2018 Jan. 32 (1):[QxMD MEDLINE Link].
Irandoost M, Zare Ghanbari M, Sakhaee F, Vaziri F, Rahimi Jamnani F, Siadat SD, et al. High rates of Mycobacterium fortuitum isolation in respiratory samples from Iranian patients with suspected tuberculosis: is it clinically important?. J Med Microbiol. 2018 Sep. 67 (9):1243-1248. [QxMD MEDLINE Link].
Adjemian J, Frankland TB, Daida YG, Honda JR, Olivier KN, Zelazny A, et al. Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA. Emerg Infect Dis. 2017 Mar. 23 (3):439-447. [QxMD MEDLINE Link].
Padilla P, Ly P, Dillard R, Boukovalas S, Zapata-Sirvent R, Phillips LG. Medical Tourism and Postoperative Infections: A Systematic Literature Review of Causative Organisms and Empiric Treatment. Plast Reconstr Surg. 2018 Dec. 142 (6):1644-1651. [QxMD MEDLINE Link].
Philips RC, Hunter-Ellul LA, Martin JE, Wilkerson MG. Mycobacterium fortuitum infection arising in a new tattoo. Dermatol Online J. 2014 Jun 15. 20(6):[QxMD MEDLINE Link].
Jiang SH, Roberts DM, Dawson AH, Jardine M. Mycobacterium fortuitum as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature. BMC Nephrol. 2012 Jun 8. 13:35. [QxMD MEDLINE Link]. [Full Text].
Sparks R, Khatami A. Mycobacterium Fortuitum Complex Skin Infection in a Healthy Adolescent. Infect Disord Drug Targets. 2014 Jul 13. [QxMD MEDLINE Link].
Singhal L, Kumari P, Gupta M, Garg K, Chander J. Submandibular Lymphadenitis in an Immunocompetent Female: Microbiological Confirmation is Need of the Hour. Infect Disord Drug Targets. 2019 Jun 19. [QxMD MEDLINE Link].
Akram SM, Koirala J. Cutaneous Cryptococcus (Cryptococcosis). 2019 Jan. [QxMD MEDLINE Link]. [Full Text].
Steinbrink J, Leavens J, Kauffman CA, Miceli MH. Manifestations and outcomes of nocardia infections: Comparison of immunocompromised and nonimmunocompromised adult patients. Medicine (Baltimore). 2018 Oct. 97 (40):e12436. [QxMD MEDLINE Link].
Tamakoshi J, Kimura R, Takahashi K, Saito H. Pulmonary Reinfection by Nocardia in an Immunocompetent Patient with Bronchiectasis. Intern Med. 2018 Sep 1. 57 (17):2581-2584. [QxMD MEDLINE Link].
ATS. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 1997 Aug. 156(2 Pt 2):S1-25. [QxMD MEDLINE Link].
Rocchetti TT, Silbert S, Gostnell A, Kubasek C, Campos Pignatari AC, Widen R. Detection of Mycobacterium chelonae, Mycobacterium abscessus Group, and Mycobacterium fortuitum Complex by a Multiplex Real-Time PCR Directly from Clinical Samples Using the BD MAX System. J Mol Diagn. 2017 Mar. 19 (2):295-302. [QxMD MEDLINE Link].
Fang H, Shangguan Y, Wang H, Ji Z, Shao J, Zhao R, et al. Multicenter evaluation of the biochip assay for rapid detection of mycobacterial isolates in smear-positive specimens. Int J Infect Dis. 2019 Apr. 81:46-51. [QxMD MEDLINE Link].
Cruz AT, Antekeier SB. Chronic multifocal Mycobacterium fortuitum osteomyelitis following penetrating plantar trauma. Am J Orthop (Belle Mead NJ). 2012 Aug. 41(8):E109-11. [QxMD MEDLINE Link].
ATS/IDSA: Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. February 2007. 175:367-416. [QxMD MEDLINE Link].
Aono A, Morimoto K, Chikamatsu K, Yamada H, Igarashi Y, Murase Y, et al. Antimicrobial susceptibility testing of Mycobacteroides (Mycobacterium) abscessus complex, Mycolicibacterium (Mycobacterium) fortuitum, and Mycobacteroides (Mycobacterium) chelonae. J Infect Chemother. 2019 Feb. 25 (2):117-123. [QxMD MEDLINE Link].
Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985 Dec. 28 (6):807-11. [QxMD MEDLINE Link].
Shen Y, Wang X, Jin J, Wu J, Zhang X, Chen J, et al. In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics. Biomed Res Int. 2018. 2018:4902941. [QxMD MEDLINE Link].
Sicairos-Ruelas EE, Gerba CP, Bright KR. Efficacy of copper and silver as residual disinfectants in drinking water. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2019. 54 (2):146-155. [QxMD MEDLINE Link].
Zheng HW, Pang Y, He GX, Song YY, Zhao YL. Antimicrobial Susceptibility Testing and Molecular Characterization of Mycobacterium fortuitum Isolates in China. Biomed Environ Sci. 2017 May. 30 (5):376-379. [QxMD MEDLINE Link].
Sanz-García F, Anoz-Carbonell E, Pérez-Herrán E, Martín C, Lucía A, Rodrigues L, et al. Mycobacterial Aminoglycoside Acetyltransferases: A Little of Drug Resistance, and a Lot of Other Roles. Front Microbiol. 2019. 10:46. [QxMD MEDLINE Link].
Das S, Garg T, Chopra S, Dasgupta A. Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria. J Antimicrob Chemother. 2019 Feb 7. [QxMD MEDLINE Link].
Esteban J, Ortiz-Pérez A. Current treatment of atypical mycobacteriosis. Expert Opin Pharmacother. 2009 Dec. 10(17):2787-99. [QxMD MEDLINE Link].
Sethi S, Arora S, Gupta V, Kumar S. Cutaneous Mycobacterium fortuitum Infection: Successfully Treated with Amikacin and Ofloxacin Combination. Indian J Dermatol. 2014 Jul. 59(4):383-4. [QxMD MEDLINE Link]. [Full Text].
CDC. Nontuberculous mycobacteria reported to the Public Health Laboratory Information System by State Public Health Laboratories United States, 1993-1996. [Full Text].
Wallace RJ, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis. 1985 Sep. 152(3):500-14. [QxMD MEDLINE Link].
Heifets LB. Antimycobacterial drugs. Semin Respir Infect. 1994 Jun. 9(2):84-103. [QxMD MEDLINE Link].
Brown-Elliott BA, Wallace RJ, Crist CJ. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother. 2002 Oct. 46(10):3283-5. [QxMD MEDLINE Link].
Wallace RJ, Brown-Elliott BA, Crist CJ. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2002 Oct. 46(10):3164-7. [QxMD MEDLINE Link].
Bhambri S, Bhambri A, Del Rosso JQ. Atypical mycobacterial cutaneous infections. Dermatol Clin. 2009 Jan. 27(1):63-73. [QxMD MEDLINE Link].
Griffith DE, Wallace RJ. New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Semin Respir Infect. 1996 Dec. 11(4):301-10. [QxMD MEDLINE Link].
Kyle SD, Porter WM. Mycobacterium chelonae infection successfully treated with oral clarithromycin and linezolid. Br J Dermatol. 2004 Nov. 151(5):1101. [QxMD MEDLINE Link].
Porat MD, Austin MS. Bilateral knee periprosthetic infection with Mycobacterium fortuitum. J Arthroplasty. 2008 Aug. 23(5):787-9. [QxMD MEDLINE Link].
Wagner D, Young LS. Nontuberculous mycobacterial infections: a clinical review. Infection. 2004 Oct. 32(5):257-70. [QxMD MEDLINE Link].
Wallace RJ, Brown-Elliott BA, Ward SC. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001 Mar. 45(3):764-7. [QxMD MEDLINE Link].
